Pregabalin Dosing

For people with postherpetic neuralgia, pregabalin dosing usually starts at 75 mg twice daily or 50 mg three times daily. The suggested starting pregabalin dosage for those with fibromyalgia is 75 mg twice daily. People who are using pregabalin to control partial seizures due to epilepsy are recommended to take a starting dose of 75 mg twice daily or 50 mg three times daily. A healthcare provider will consider several factors when making pregabalin dosing recommendations, such as other drugs you may be taking.
 

An Introduction to Pregabalin Dosing

The dose of pregabalin (Lyrica®) that your healthcare provider recommends will vary depending on a number of factors, including:
 
  • The medical condition being treated
  • Other medications you may be taking
  • Other medical conditions you may have.
     
As always, do not adjust your pregabalin dosage unless your healthcare provider specifically instructs you to do so.
 
Pregabalin Dosing for Diabetic Peripheral Neuropathy
The recommended starting pregabalin dose for treating nerve pain due to diabetic neuropathy is pregabalin 50 mg three times daily. Your healthcare provider may increase your dose (up to a maximum of pregabalin 100 mg three times daily) within a week if necessary to control your pain -- and if you tolerate pregabalin well. If you have kidney disease, you may need a lower pregabalin dose.
 
Pregabalin Dosing for Epileptic Seizures
The recommended starting pregabalin dose for controlling partial seizures in people with epilepsy is pregabalin 75 mg twice daily or pregabalin 50 mg three times daily. If necessary to control your seizures, your healthcare provider may increase your dose, up to a maximum of pregabalin 200 mg three times daily. It is important to understand that pregabalin is approved to treat seizures only when used in combination with other seizure medications. If you have kidney disease, you may need a lower pregabalin dose.
(Pregabalin Dosing Continued: Page 2)
Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;
Other Articles in This eMedTV Presentation